Search Results 1921-1930 of 20084 for Receptor

1. A Study To Evaluate The Safety And Tolerability Of TreT In Subjects With PAH Currently Using Tyvaso - Mayo Clinic

   If currently receiving other approved background therapy (e.g., endothelin receptor antagonist or phosphodiesterase type 5 inhibitor or both), the subject ...

2. A Study Of Latanoprost In Open Angle Glaucoma And Ocular Hypertension Patients - Mayo Clinic

   ... receptor blockers. Recent change in medications that are known to affect IOP within 30 days prior to the screening visit and during the study including ...

3. A Study To Evaluate Intravenous Iloprost In Subjects With Symptomatic Raynaud's Phenomenon Secondary To Systemic Sclerosis - Mayo Clinic

   Subjects who have taken or are currently taking any parenteral, inhaled, or oral prostacyclin or prostacyclin receptor agonists (e.g., epoprostenol ...

4. A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma - Mayo Clinic

   * Note: In Part A, prior exposure to anti g-protein-coupled receptor, class c, group 5, member d (GPRC5D) therapy and anti B-cell maturation antigen (BCMA) ...

5. A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease - Mayo Clinic

   ... receptor blockers are allowed), CTLA4 inhibitors, and PD-1/PD-L1 inhibitors). * Ongoing chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) of ...

6. For Better, For Worse - Mayo Clinic News Network

   "We are able to identify molecular features, receptors and genetic markers. These patterns may offer clues as to how the tumor will respond to different ...

7. A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   ... receptor T-cell \[CAR-T\] directed against BCMA). Exclusion Criteria: - Arm A: Received BCMA-targeted therapy. Note: Other protocol defined Inclusion ...

8. Sarosh R. Irani, B.M., B.Ch., D.Phil.

   I discovered LGI1 and CASPR2 antibodies, and have cared for over 300 patients with LGI1, CASPR2, NMDA, AQP4, MOG and GABA receptor-antibodies and ...

9. Tradipitant After GLP-1R Agonist In Healthy, Overweight, or Class I or II Obese Volunteers - Mayo Clinic

   Uncontrolled blood glucose (including HbA1C >7 or metabolic crisis in past 60 days) or treatment with GLP-1 receptor agonist (e.g. dulaglutide, semaglutide ...

10. A Study to Determine the Effect of Distance Reiki on Patient Reported Quality of Life (PRQoL) and Immunity Among Multiple Myeloma Patients - Mayo Clinic

    ... receptors (TCRs) for assessment of immune repertoire diversity by iRepertoire®. Participation eligibility. Participant eligibility includes age, gender, type ...